PDP Pediapharm

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES


Pediapharm Inc. ("Pediapharm") (TSX VENTURE:PDP) announced today that further to
its press release of July 2nd, 2014, a Special Access Program' (SAP) from Health
Canada has been initiated for Naproxen suspension. This program allows
physicians to prescribe the product to their patients when no commercially
available alternatives are available. This program has been initiated at the
request of physicians mainly treating patients suffering of Juvenile Rheumatoid
Arthritis (JRA). The product will be made available through Pediapharm and the
SAP will be in place until the availability of Pediapharm Naproxen Suspension. 


On July 2, 2014, Pediapharm announced an asset purchase agreement regarding the
Canadian rights to naproxen suspension from Hoffman-La Roche Limited ("Roche").
Roche will retain the Naprosyn(TM) trademark and retains all product rights to
the other oral dosage forms under this brand.


Information regarding this program can be obtained by contacting the SAP office
or by visiting http://drugshortages.ca 


Information will also be disseminated by the Canadian Rheumatology Association
to its member.


About Hoffmann-La Roche Limited

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is
the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche
is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that enable
tangible improvements in the health, quality of life and survival of patients.
In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion
Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more
information, please visit www.roche.com.


Naprosyn(TM) is a trademark of Hoffmann-La Roche Limited.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. 


FORWARD LOOKING STATEMENTS FOR PEDIAPHARM

This news release contains forward-looking statements and other statements that
are not historical. Such forward-looking statements are subject to known and
unknown risks, uncertainties and assumptions that could cause actual results to
vary materially from target results and the results or events predicted in these
forward-looking statements. As a result, investors are cautioned not to place
undue reliance on these forward-looking statements.


The forward-looking statements contained in this news release are made as of the
date of this release. Except as required by applicable law, the Corporation
disclaims any intention and assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Forward-looking information reflects the current
expectations or belief of the Corporation based on information currently
available and such information is subject to a number of assumptions, risks and
uncertainties described in details at pp. 35 to 41 of the Management Information
Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on
SEDAR at www.sedar.com and other risks associated with being a specialty
pharmaceutical company.


For more information about Pediapharm or its products, please visit
www.pedia-pharm.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pediapharm Inc.
Sylvain Chretien
President and Chief Executive Officer
+1-514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com


Pediapharm Inc.
Roland Boivin
Chief Financial Officer
+1-514-762-2626 ext. 202
roland.boivin@pedia-pharm.com


Relations Publiques Paradox Public Relations Inc.
Carl Desjardins
+1-514-341-0408
carldesjardins@paradox-pr.ca


Hoffmann-La Roche Limited
Lee Rammage
Manager, Corporate Relations
+1-416-560-9850
lee.rammage@roche.com

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
From Oct 2024 to Nov 2024

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
From Nov 2023 to Nov 2024